Parkinson's Disease Trial, Not Yet Recruiting NCT07139756 Sponsor: Centre Hospitalier Universitaire Vaudois Condition: Parkinson's Disease
Back to Parkinsons Disease

Parkinson's Disease Trial, Not Yet Recruiting

NCT07139756
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • A person has signed the informed consent form agreeing to take part in the study
  • A person is aged 18 years or older but under 75 years old
  • A person has a normal blood pressure reading in the clinic (below 140/90 mmHg)
  • Women who could become pregnant must be using, or willing to use during the study, a reliable contraception method that is compatible with MRI scans
  • A person meets the Movement Disorder Society's clinical criteria for "clinically established Parkinson's disease"
  • A person's Parkinson's disease is being treated with dopamine replacement therapy
  • A person is willing and able to attend all study visits and follow study procedures
  • A person is independent in their daily life
  • A person's Schellong test result (a test measuring blood pressure changes when standing up) shows either orthostatic hypotension — a drop in systolic blood pressure of more than 20 mmHg or diastolic blood pressure of more than 10 mmHg — (for the group with this condition) or no such drop (for the group without this condition)

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • A person whose Schellong test shows a significant drop in blood pressure when standing (systolic drop of more than 20 mmHg or diastolic drop of more than 10 mmHg) (confirm with trial site, as this criterion may apply only to the healthy volunteer group)
  • Women who are pregnant or breastfeeding
  • A person who refuses to be told about any unexpected findings discovered during the study
  • A person who takes any medication — either short-term or ongoing — other than oral contraception (this applies to the healthy volunteer phase; confirm with trial site)
  • A person who has abnormal blood test results considered clinically significant by the investigator
  • A person who has a chronic or acute illness
  • A person who is currently participating in another clinical trial
  • A person who has donated blood in the 60 days before the study (confirm with trial site for which phase this applies)
  • A person who has a reason they cannot have an MRI scan
  • A person who is unable to follow the study procedures
  • A person who has a hierarchical relationship with, or is a family member of, the study investigator
  • A person who is unable to give informed consent (Phase 2)
  • A person whose 24-hour ambulatory blood pressure monitoring shows a reading above 180/110 mmHg (Phase 2)
  • A person whose kidney function test (eGFR) result is below 45 ml/min/1.73m², as calculated by the CKD-EPI method (Phase 2)
  • A person who has an allergy to the components of the contrast agent Sonovue® used in the study (Phase 2)
  • A person who lives in an institution (Phase 2)
  • A person who has dementia (Phase 2)
  • A person who has type 2 diabetes (Phase 2)
  • A person who has had a stroke or heart attack in the past 6 months (Phase 2)
  • A person who has donated blood in the previous 6 months (Phase 2)
  • A person who is currently undergoing active cancer treatment (Phase 2)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 24 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Grégoire Wuerzner, CHUV

Phone: +41 79 556 1973

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Centre Hospitalier Universitaire Vaudois
Registry
ClinicalTrials.gov
Start date
1 October 2025
Est. completion
30 September 2027

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Differences and changes in BOLD fMRI signal intensity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 24 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov